WELLELL (4106) reported revenue of NT$198.2 million for Oct 2026, -5.1% year on year and -12.7% from the previous month. Revenue for Jan–Oct 2026 was NT$2.13 billion (+7.3% year on year).
In Oct 2026, it ranked No. 42 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$198.2 million | -5.1% | -12.7% |
| Sep 2026 | NT$227.1 million | +14.4% | -1.7% |
| Aug 2026 | NT$230.9 million | +14.0% | +4.6% |
| Jul 2026 | NT$220.7 million | +1.2% | -17.0% |
| Jun 2026 | NT$265.8 million | +26.8% | +42.6% |
| May 2026 | NT$186.4 million | -9.5% | -15.9% |
| Apr 2026 | NT$221.7 million | +17.5% | +6.6% |
| Mar 2026 | NT$207.9 million | +7.0% | +10.4% |
| Feb 2026 | NT$188.3 million | +10.6% | +0.7% |
| Jan 2026 | NT$187 million | -2.4% | -14.2% |
| Dec 2025 | NT$218 million | +1.9% | +10.4% |
| Nov 2025 | NT$197.5 million | +1.9% | -5.4% |
| Oct 2025 | NT$208.9 million | +1.5% | +5.2% |
| Sep 2025 | NT$198.5 million | +18.0% | -2.0% |
| Aug 2025 | NT$202.5 million | +12.1% | -7.2% |
| Jul 2025 | NT$218.1 million | +13.0% | +4.0% |
| Jun 2025 | NT$209.7 million | +10.8% | +1.8% |
| May 2025 | NT$206 million | +7.2% | +9.1% |
| Apr 2025 | NT$188.8 million | -7.0% | -2.9% |
| Mar 2025 | NT$194.4 million | -6.6% | +14.2% |
| Feb 2025 | NT$170.2 million | -6.7% | -11.2% |
| Jan 2025 | NT$191.6 million | -25.2% | -10.5% |
| Dec 2024 | NT$214 million | -7.1% | +10.4% |
| Nov 2024 | NT$193.8 million | -16.7% | -5.9% |
| Oct 2024 | NT$205.8 million | -4.6% | +22.4% |
Jan–Oct 2026 cumulative: NT$2.13 billion (+7.3% YoY)
Other Biotech & Medical companies
Compare with peers: WELLELL vs PEC / WELLELL vs Lotus Pharm / WELLELL vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16